Process Chemometrics Patents: Who Leads, Where the Gaps Are 2026
- 37.9% sits with five assignees. 262 of 691 records concentrate at the top, while the ranked field runs 100 companies deep into single-filing entrants.
- Filing has plateaued, not fallen. 2021 to 2024 filings held flat at 6 to 6, a 0% span; 2025's count of 27 is provisional given the ~18-month publication lag.
- Diagnosis claims outweigh instrumentation build-out. A61B appears on 43.8% of records against G01N's 57.3%, showing calibration transfer work is as much a clinical claim space as an analytical one.
Filing growth compares 2021 (6 records) with 2024 (6) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 691 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This dataset tracks patent families at the intersection of process chemometrics and calibration model transfer — the methods used to build, validate and maintain multivariate calibration models as instruments, reagents and reference methods drift over time. The search combines core chemometric terms with lifecycle concerns: outlier detection, model updating, validation strategy, spectral preprocessing and reference method error. That pairing captures filings from both classical process analytical technology (PAT) and non-invasive clinical measurement, which explains why material analysis and diagnosis classes both appear heavily in the composition data below.
691 records span 2015 through the 2026 cut-off, with receiving-office activity concentrated in the United States, EPO and WIPO PCT filings, plus meaningful Canadian and Australian counts. The most-cited records date from the 1990s and early 2000s non-invasive glucose measurement wave, a reminder that citation strength in this corpus favours older foundational work over current filing activity.
Filing trend and technology composition
Two views of the same 691-record set: how filing volume has moved year over year, and which IPC subclasses carry the claim density.
Filing trend, 2017-2026
Annual counts run from 3 in 2017 to a peak of 27 in 2025, with 2021-2024 flat at 6 filings (0% change). Because publication lags filing by roughly 18 months, the 2025 and 2026 figures will keep rising as later filings publish — they should not be read as a peak-and-decline pattern yet.
IPC subclass composition
G01N (material analysis and testing) and A61B (diagnosis and surgery) dominate at 57.3% and 43.8% of the 691 records respectively, with G06F (digital data processing, 19.2%) and G01J (radiation and light measurement, 10.4%) forming a second tier. Records commonly carry multiple classes, so these shares sum to well over 100%.
Shares are the percentage of the 691 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Process Chemometrics and Model Transfer with Eureka
This page is one run against one query. Ask Eureka your own question about process chemometrics and model transfer and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative filing and most-cited prior art
Focusing linear model correction and linear model correction for multivariate calibration model maintenance
A device obtains a master beta coefficient from a master calibration model tied to a master instrument, then runs constrained optimization against a scouting set of spectra to determine a pair of transferred beta coefficients for a target instrument. The final transferred beta coefficient is derived from this pair, giving a defined path for moving a calibration model from one instrument to another without full recalibration.Filed by Viavi Solutions, published 2023-05-25 — squarely inside the model-transfer segment of this landscape.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US6574490B2 | System for non-invasive measurement of glucose in humans | 1,013 |
| 2 | US6280381B1 | Intelligent system for noninvasive blood analyte prediction | 955 |
| 3 | US4975581A | Method of and apparatus for determining the similarity of a biological analyte from a model constructed from … | 835 |
| 4 | US20030109951A1 | Monitoring system for an industrial process using one or more multidimensional variables | 772 |
| 5 | US6990364B2 | Noninvasive measurement of glucose through the optical properties of tissue | 615 |
| 6 | US5494032A | Oximeter for reliable clinical determination of blood oxygen saturation in a fetus | 603 |
| 7 | US5355880A | Reliable noninvasive measurement of blood gases | 596 |
| 8 | US6640117B2 | Method and apparatus for minimizing spectral effects attributable to tissue state variations during NIR-based… | 568 |
| 9 | US7027848B2 | Apparatus and method for non-invasive spectroscopic measurement of analytes in tissue using a matched referen… | 564 |
| 10 | US7606608B2 | Optical sampling interface system for in-vivo measurement of tissue | 510 |
Citation counts favour older filings simply by virtue of time in the corpus; treat them as a signal of foundational influence, not current relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Three read-throughs from the concentration, trend and citation data above.
The top of the field is settled, the middle is open
Five assignees hold 262 of 691 records (37.9%), and the top ten hold 374 (54.1%). That leaves nearly half the corpus spread across a long tail running to 100 ranked companies, many with a handful of filings each — a sign that core calibration-transfer methods are claimed but many application-specific adaptations are not.
Flat filing, not declining filing
The three-year span from 2021 to 2024 shows no net growth in annual filings (6 to 6). Combined with a rise to 27 in 2025, the honest read is a field that had plateaued through the early 2020s and may be picking back up — the most recent years are still incomplete due to publication lag.
Clinical calibration transfer is not a side case
A61B appears on 43.8% of the 691 records, nearly matching G01N's 57.3%. Non-invasive measurement patents — glucose monitoring chief among them by citation count — sit inside the same claim space as industrial process analytics, so a freedom-to-operate review for one side of this field should check the other.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to process chemometrics and model transfer, with the prior art for and against each one.
Who holds the claim space
The leader holds 86 records against a fifth-place figure of 28 and a tenth-place figure of 17 — a steep drop-off after the top few, then a long, thin tail.
A single assignee well ahead of the field
The top-ranked assignee's count of 86 records is more than triple the fifth-place figure of 28, indicating a sustained, multi-decade filing program rather than a single technology push.
A competitive second tier
Between fifth place (28 records) and tenth place (17 records) sits a cluster of assignees close enough in volume that new filings could reshuffle the order, unlike the wide gap separating the leader from the rest.
Many single- or low-filing entrants
The ranking runs the full 100 companies the dataset returns, most holding only a few records. That breadth suggests the underlying methods are accessible enough for smaller players and academic groups to file narrow, application-specific claims.
| Assignee | Recent year | YoY |
|---|---|---|
| Sensys Medical Inc | 0 | — |
| ExxonMobil Technology & Engineering Co | 0 | — |
| Instrumentation Metrics Inc | 0 | — |
| Automotive Coalition for Traffic Safety Inc | 0 | — |
| X Development LLC | 0 | -100% |
| GLT Acquisition | 0 | — |
| Bayer Pharma AG | 0 | — |
| Rio Grande Medical Technologies | 0 | — |
Where to take this analysis
The dataset points to two immediate next steps for a team evaluating this space.
Check freedom-to-operate against the top 10
With 54.1% of records held by ten assignees, a targeted claim-chart review of that group is more efficient than screening the full 100-company ranking before scoping new filings.
Run a freedom-to-operate check in EurekaTrack the 2025-2026 filing rebound
The jump to 27 filings in 2025 after a flat 2021-2024 span is worth monitoring as later publications land, particularly to see which assignees are driving the increase.
Set up filing alerts in EurekaCommon questions on this landscape
Calibration model transfer refers to methods that let a multivariate calibration model built on one instrument, or under one set of conditions, remain valid on a different instrument or after conditions drift. Rather than rebuilding a model from scratch, techniques such as beta-coefficient correction, spectral standardization and scouting-set optimization adjust the existing model to fit new data. This matters commercially because rebuilding a validated calibration model can be slow and costly, especially in regulated environments like pharmaceutical process analytical technology or clinical diagnostics. The representative patent in this landscape, filed by Viavi Solutions, is a direct example of this transfer approach.
The dataset's assignee ranking is led by one company holding 86 of the 691 records in scope, well ahead of the fifth-ranked assignee at 28 and tenth-ranked at 17. Beyond the top ten, which together hold 54.1% of all records, the field spreads across a long tail of 100 ranked assignees including instrument makers, pharmaceutical companies and universities. This pattern indicates a mature core method set controlled by a small group, with room for narrower application-specific claims further down the ranking.
Filings were flat between 2021 and 2024, moving from 6 to 6 annual records for a 0% three-year change, before rising to a peak of 27 in 2025. Because patent publication typically lags filing by around 18 months, the 2025 and 2026 figures are still incomplete and will likely revise upward. The honest characterization is a plateau through the early 2020s followed by a possible pickup, not a declining field.
Non-invasive measurement techniques, particularly optical glucose monitoring, rely on the same multivariate calibration and model-transfer methods used in industrial process analytical technology. That overlap is why A61B (diagnosis and surgery) appears on 43.8% of the 691 records, close behind G01N (material analysis and testing) at 57.3%. Several of the most-cited records in this corpus are non-invasive glucose measurement patents from the 1990s and early 2000s, reflecting how foundational that clinical application was to the broader chemometrics field. Anyone scoping industrial PAT claims should still check clinical-side patents for overlapping calibration-transfer methods.
The clearest openings sit in narrower, application-specific branches rather than the core calibration-transfer math, which the leading assignees have claimed heavily. Sub-areas such as automated reference-method error correction, cross-instrument spectral grid alignment, and bioreactor-specific calibration drift monitoring show filing activity but no dominant claim-holder yet. The long tail of the assignee ranking, where most of the 100 ranked companies hold only a handful of records each, supports this reading: the foundational methods are occupied, but many specific implementations are not.
Research Process Chemometrics and Model Transfer in depth with Eureka
Go past this page: query the whole process chemometrics and model transfer corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.